Novartis R&D Portfolio Grows 44% Since 2000; Half Of Projects Are NMEs
Executive Summary
Novartis' clinical R&D portfolio has grown 44% over the last four years, with new molecular entities representing about half the drugs in development, Global Pharma Development Head Joerg Reinhardt, PhD, said Nov. 19 during Novartis' R&D day in New York
You may also be interested in...
Novartis names once-yearly zoledronic acid Aclasta
Aclasta will be the trade name for Novartis' once-yearly I.V. infusion formulation of zoledronic acid for treatment of Paget's disease. The priority review date on the Aclasta NDA is in March, the company said. Novartis anticipates a 2007 filing of Aclasta in treatment of osteoporosis (1"The Pink Sheet" Nov. 24, 2003, p. 29). Novartis also markets zoledronic acid under the trade name Zometa for treatment of prostate cancer...
Novartis names once-yearly zoledronic acid Aclasta
Aclasta will be the trade name for Novartis' once-yearly I.V. infusion formulation of zoledronic acid for treatment of Paget's disease. The priority review date on the Aclasta NDA is in March, the company said. Novartis anticipates a 2007 filing of Aclasta in treatment of osteoporosis (1"The Pink Sheet" Nov. 24, 2003, p. 29). Novartis also markets zoledronic acid under the trade name Zometa for treatment of prostate cancer...
Abbott To Cut Rx Development Costs In Half By Increasing Candidate Attrition
Abbott believes it can cut the cost of drug development in half by increasing the rate of attrition in the discovery phase, the company said Feb. 9 at a drug development summit sponsored by R&D Directions in Phoenix